Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nefecon OLE in IgA Nephropathy (China)
NCT05534919Phase 3Completed
- Sponsor
- Everest Medicines
- Start
- Dec 2022
- Primary completion
- Jul 2024
- Modality
- Drug Delivery Systems, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of nefecon in IgA nephropathy (IgAN), sponsored by Everest Medicines. Started Dec 2022; status: completed.
02
Drugs
nefecon
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05534919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05534919.